1. NextAmp™ Analysis System
2. PanelChip®
3. DigiChip™ Digital PCR
4. ThyroSCAN
5. FusionQuest

Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit

TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.